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Abstract
Aims:Oxidative stress and mitochondrial dysfunction participate together in the development of heart failure (HF).
mRNA levels of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that produces hydrogen peroxide
(H2O2), increase in several models of cardiomyopathies. Therefore, we hypothesized that an increase in cardiac
MAO-A could cause oxidative stress and mitochondrial damage, leading to cardiac dysfunction. In the present
study, we evaluated the consequences of cardiac MAO-A augmentation on chronic oxidative damage, cardio-
myocyte survival, and heart function, and identified the intracellular pathways involved. Results: We generated
transgenic (Tg) mice with cardiac-specific MAO-A overexpression. Tg mice displayed cardiac MAO-A activity
levels similar to those found in HF and aging. As expected, Tg mice showed a significant decrease in the cardiac
amounts of the MAO-A substrates serotonin and norepinephrine. This was associated with enhanced H2O2 gen-
eration in situ and mitochondrial DNA oxidation. As a consequence, MAO-A Tg mice demonstrated progressive
loss of cardiomyocytes by necrosis and ventricular failure, which were prevented by chronic treatment with the
MAO-A inhibitor clorgyline and the antioxidant N-acetyl-cystein. Interestingly, Tg hearts exhibited p53 accumu-
lation and downregulation of peroxisome proliferator-activated receptor-c coactivator-1a (PGC-1a), a master reg-
ulator of mitochondrial function. This was concomitant with cardiac mitochondrial ultrastructural defects and ATP
depletion. In vitro, MAO-A adenovirus transduction of neonatal cardiomyocytes mimicked the results in MAO-A
Tg mice, triggering oxidative stress-dependent p53 activation, leading to PGC-1a downregulation, mitochondrial
impairment, and cardiomyocyte necrosis. Innovation and Conclusion: We provide the first evidence that MAO-A
upregulation in the heart causes oxidative mitochondrial damage, p53-dependent repression of PGC-1a, cardio-
myocyte necrosis, and chronic ventricular dysfunction. Antioxid. Redox Signal. 18, 5–18.
Introduction
Heart failure (HF) is among the most prevalent dis-eases in developed countries. Reactive oxygen species
(ROS) are believed to play a prominent role in triggering
ventricular damage, thus accelerating the progression of
HF (10). At the molecular level, chronic exposure to ROS
leads to accumulation of oxidized DNA, proteins, and lipids.
This results in cardiomyocyte dysfunction and death, a de-
termining factor in ventricular remodelling and failure (8).
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Mitochondria in cardiomyocytes are at particular risk for
oxidative stress (37). To provide energy to meet the high
demand, the heart contains numerous mitochondria and is
especially vulnerable to mitochondrial dysfunction. Mi-
tochondrial oxidative damage such as DNA mutations have
been related to mitochondrial dysfunction, decline in cardio-
myocyte function and death (4, 17, 37, 43). In addition, a de-
crease in energy metabolism in several animal models of HF
and in humans has been linked to the downregulation of
peroxisome proliferator-activated receptor-c coactivator-1a
(PGC-1a) (32, 33), a master regulator of mitochondrial func-
tion that could represent a preferential target for ROS.
Despite accumulative evidence of the deleterious effect of
ROS in the failing heart, the precise sources of ROS overpro-
duction remain to be identified. Specific targeting of ROS
sources could provide a more effective therapy for HF than
global antioxidant therapies, which have given conflicting
results in clinical trials (10). Monoamine oxidase-A (MAO-A)
is located in the outer mitochondrial membrane of cardio-
myocytes and plays a major role in serotonin and catechol-
amine metabolism (42). MAO-A catalyses the oxidative
deamination of monoamines and generates hydrogen perox-
ide (H2O2), aldehyde, and ammonia as by-products (Supple-
mentary Fig. S1A; Supplementary Data are available online at
www.liebertpub.com/ars). Thus, MAO-A has been proposed
as a relevant source of oxidative stress in the heart. Indeed, a
deleterious role for MAO-A/ROS pathway has been dem-
onstrated in acute situations such as ischemia-reperfusion
where pharmacological or genetic inactivation of MAO-A
prevented cardiomyocyte death (6, 30). In addition, genetic
and/or pharmacological inhibition of MAO-A prevented the
augmentation of ROS and left ventricular dysfunction in mice
with ventricular pressure overload (14).
Interestingly, MAO-A mRNA expression appears to be
enhanced in several models of HF (14, 16) as well as in
the aging rat heart (24). However, the effect and down-
stream targets of such chronic increase in MAO-A expression
are presently unknown. To address this question, we com-
bined in vivo and in vitro approaches to analyze the functional
consequences of cardiomyocyte MAO-A overexpression
using transgenic (Tg) mice and adenoviral-transduced cardi-
omyocytes.
We found that increasing MAO-A expression to patho-
physiological levels observed in failing and aging hearts
was sufficient per se to cause chronic oxidative stress, mito-
chondrial damage, and PGC-1a downregulation, thereby
contributing to cardiomyocyte necrosis. Consequently, MAO-
A Tg mice died prematurely from dilated HF. Interestingly,
we identified for the first time p53 as a major signaling
intermediate in H2O2-induced mitochondrial damage, PGC-
1a downregulation and cardiomyocyte necrosis linked to
MAO-A activation.
Results
Myocardial MAO-A activity increases during ventricular
hypertrophy, failure and aging
We first analyzed changes in myocardial MAO-A activity
in response to various stresses. In a rat model of pressure
overload induced by ascendant aortic banding (7), MAO-A
activity was significantly increased at the stage of compen-
sated hypertrophy (5 weeks) and decompensated HF
(15 weeks), compared to age-matched sham rats (Fig. 1A).
Next, we examined the effect of aging on cardiomyocyte
MAO-A activity. MAO-A activity increased gradually be-
tween 2 and 24 months in cardiac homogenates (Fig. 1B).
Interestingly, a profound increase in MAO-A activity was
also observed in cardiacmyocytes isolated from senescent rats
(24-months old) compared to those isolated from 2-months
old rats (Fig. 1C).
Tg mice overexpress an active MAO-A enzyme
in cardiac mitochondria
In order to mimic changes observed during ventricular
pressure overload and aging, we generated mice with cardi-
omyocyte-specific overexpression of MAO-A under the con-
trol of the a-myosin heavy chain (MHC) promoter. Two
independent lines of Tg mice were propagated with different
levels of MAO-A activity of 9336 – 2139 pmol/mg/min for Tg
61 and 40291 – 11912pmol/mg/min for Tg 113 (Fig. 2A). The
levels ofMAO-A expression in Tg61were in the same order of
magnitude than those observed in failing and aging hearts
(Fig. 1A, B). However, since endogenous MAO-A activity in
the mice heart (40 pmol/mg/min) is much lower than in
rat heart, the difference observed between Tg61 and non-
transgenic (NTg)micewas higher than that observed between
pathological and normal rat hearts. The level of MAO-A
mRNA overexpression in line 61 was preserved until 6
months (Supplementary Fig. S1B). Western blot analysis
demonstrated specific upregulation of MAO-A in cardiac but
not liver homogenates compared to NTg littermates (Fig. 2B).
In addition, we verified that overexpressed MAO-A was
correctly targeted to mitochondria and maintained its cata-
lytic activity. Double immunofluorescence staining on heart
sections showed enhanced levels of MAO-A in Tg 61 mice
compared to NTg, and colocalization with the mitochondrial
protein Cox IV (Fig. 2C). We also found that mitochondria
isolated from Tg 61 mice produced greater amounts of H2O2
in presence of theMAO substrate tyramine compared to NTg,
an effect that was inhibited by 96% with the MAO inhibitor
pargyline (Fig. 2D). Finally, we measured by high perfor-
mance liquid chromatography (HPLC) the levels of MAO-A
substrates serotonin (5-hydroxy-tryptamine [5-HT]) and
norepinephrine (NE), along with their respective MAO
metabolites 5-hydroxyindoleacetic acid (5-HIAA) and dihy-
droxyphenylglycol (DHPG) in cardiac homogenates. As
shown in Figure 2E and F, the ratios of 5-HIAA/5-HT and
DHPG/NE were significantly elevated in Tg 61 mice, as a re-
sult of both substrate depletion and metabolite accumulation.
Innovation
Oxidative stress and mitochondrial dysfunction par-
ticipate together in the development of heart failure (HF),
but the precise source and mechanisms of action are still a
matter of debate. In this article, we show for the first time
that enhancing monoamine oxidase-A expression, as
observed in different models of cardiomyopathy, causes
oxidative mitochondrial damage, p53-dependent peroxi-
some proliferator-activated receptor-c coactivator-1a
(PGC-1a) repression, cardiomyocyte necrosis, and chronic
ventricular dysfunction leading to HF.
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Altogether, our observations demonstrate that oxidative me-
tabolism of 5-HT andNE at the mitochondria is potentiated in
MAO-A Tg mice.
MAO-A Tg mice develop dilated cardiomyopathy
To evaluate the consequences of MAO-A upregulation on
cardiac morphology and function, echocardiographies were
performed in Tg 61 andNTgmice at different ages. Since NTg
mice between 3 and 7 months displayed similar morpholog-
ical parameters, we choose to present only one time-point (3
months) for NTg mice in Table 1. At 1.5 months, ventricular
function was not modified in Tg 61 compared to NTg mice
(data not shown). However, there was a significant and pro-
gressive decrease in fractional shortening (FS) in Tg 61 mice
between 3 and 7 months, accompanied by left-ventricular
dilatation (Table 1). Myocardial hypertrophy was not ob-
served since neither diastolic septal wall thickness (DSWT)
nor posterior wall thickness (PWT) was modified (Table 1).
HF was confirmed in 7-month-old Tg mice by a significant
increase in lung weight/body weight ratio (7.66 – 0.47mg/g
vs. 5.41 – 0.27mg/g, p< 0.05) compared to NTg, indicative of
pulmonary congestion. As a consequence, life span was se-
verely reduced in Tg 61 mice with a maximum survival
around 9 months (Supplementary Fig. S2A). To demonstrate
that the deleterious effects of MAO-A upregulation depended
on its catalytic activity, we performed echocardiographies on
Tgmice treatedwith theMAO-A inhibitor clorgyline from the
age of 1 to 5 months. Chronic administration of clorgyline
(10mg/kg/day) prevented left ventricle (LV) dysfunction
and chamber dilatation in Tg mice, compared to untreated Tg
mice (Table 1). It is noteworthy that another line of Tg mice
(Tg 113), which express a higher amount ofMAO-A, shows an
accelerated cardiomyopathy, with a dramatic drop in FS at 2
months, ventricular dilatation, and decreased survival (Sup-
plementary Fig. S2A, B). Altogether, our data demonstrate
that an increase in MAO-A catalytic activity induces pro-
gressive dilated cardiomyopathy and HF in mice.
Evidence of cell death in the hearts of MAO-A Tg mice,
accompanied by inflammatory response, reactive
cellular hypertrophy, and fibrosis
To gain more insights into the deleterious effects of myo-
cardial MAO-A upregulation, we performed histological
examinations. The most striking feature in Tg hearts was
myocardial disarray (Fig. 3A, upper panel). Cardiomyocyte
dropout was also evidenced in Tg hearts (Fig. 3A, B), starting
around the age of 1.5 months (- 17%, nonsignificant), reach-
ing - 51% ( p< 0.01) at the age of 3 months and remaining
stable until 6 months, compared to NTg mice. As a compen-
satory response, residual cardiomyocytes were hypertro-
phied and interstitial fibrosis was enhanced in Tg mice (Fig.
3A, B). Chronic MAO-A inhibition with clorgyline prevented
cardiomyocyte dropout, hypertrophy, and fibrosis in Tg mice
(Fig. 3A, B). Interestingly, histological findings were recapit-
ulated in Tg 113 mice (Supplementary Fig. S2C). In addition,
Tg 61 cardiac mRNA expression analysis confirmed histo-
logical findings, with upregulation of pro-inflammatory cy-
tokines as soon as 1.5 months after birth, re-expression of the
fetal gene program, and upregulation of extracellular matrix
components (Supplementary Fig. S3).
As we found that cardiomyocyte loss occurred between 1.5
and 3 months in Tg mice, we tested for the presence of ne-
crosis and apoptosis to clarify the underlying mechanism of
myocyte death at those ages. Regarding necrosis, plasma
levels of troponin-I (a sensitive marker of myocyte necrosis)
were greatly increased in young Tg mice, while they were
undetectable in NTg mice (Fig. 3C). This was in agreement
with histological observations at 1.5, 3 (not shown), and 6
months (Fig. 3A, upper panel) that highlighted necrotic areas
with disruption of myofibrils, cell debris, loss of nuclei,
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FIG. 1. Monoamine oxidase-A (MAO-
A) activity is increased in response to
hypertrophy, failure, and aging in the
heart. (A) MAO-A activity in cardiac
homogenates from rats with ascendant
aortic banding (Band) for 5 weeks (hy-
pertrophy, n= 5) or 15 weeks (heart
failure [HF], n= 5) compared to age-
matched sham (n= 5). (B) MAO-A ac-
tivity in cardiac homogenates from
young (2 months), middle age (12
months), and senescent rats (24 months)
(n= 6). (C) MAO-A activity in isolated
rat cardiomyocytes at the ages indi-
cated (n= 3–4). (*p< 0.05, **p< 0.01,
***p< 0.001 vs. indicated value).
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smudging, and scattered leukocytes in Tg mice (see arrow in
Fig. 3A). Concerning apoptosis, terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining (Fig.
3D) or caspase-3 cleavage (Fig. 3E) were not modified in 1.5-
month-old Tg mice. A small increase in the number of apo-
ptotic nuclei was observed at 3 months but did not correlate
with caspase-3 activation (not shown). In contrast, the ex-
pression of the cell death intermediate p53 was significantly
increased in Tg hearts compared to NTg (Fig. 3F) at an early
age (1.5 months). As p53 is known to participate, not only in
apoptotic but also in necrotic death induction (38, 41), our
results suggest that it could be linked to cardiomyocyte ne-
crosis signaling in MAO-A Tg mice. Altogether, although
apoptosis cannot be completely excluded, our results point
toward cell necrosis as the predominant mechanism for car-
diomyocyte dropout in MAO-A-overexpressing mice.
Oxidative stress is increased in hearts from MAO-A
Tg mice and participates in the development
of dilated cardiomyopathy
First, we evaluated DNA oxidation, a sensitive marker of
oxidative stress, in cardiac sections from Tg 61 mice using 8-
OH-dG staining. We found that DNA oxidation was signifi-
cantly increased in Tg hearts compared to NTg hearts as soon
as 1.5 months, 3 months (Supplementary Fig. S4A), and 6
months (Fig. 4A). Interestingly, a prominent cytoplasmic
staining indicated that mitochondrial DNA was particularly
susceptible to oxidation in this model. Chronic treatment of
Tg mice with clorgyline prevented accumulation of 8-OH-dG
(Fig. 4A). In order to determine whether H2O2 was over-
produced in Tg 61 mice, we used an H2O2-sensitive electrode
that detects the concentration of H2O2 in ventricles of
FIG. 2. MAO-A Tg mice
overexpress an active MAO-
A enzyme, specifically in
cardiac mitochondria. (A)
Cardiac MAO-A activity in
nontransgenic (NTg), trans-
genic (Tg) 61, and Tg 113
mice at 1.5 months (n = 3).
The DNA transgene is re-
presented above the histo-
gram, with the a-myosin
heavy chain (a-MHC) pro-
moter in front of the MAO-A
cDNA. (B) Representative
MAO-A immunoblot on car-
diac and liver homogenates
in NTg, Tg 61, and Tg 113
mice. (C) Double immuno-
fluorescence staining on heart
sections using MAO-A and
Cox-IV antibodies (· 1000) at
3 months. (D) Hydrogen
peroxide (H2O2) measure-
ments on isolated cardiac
mitochondria incubated with
Tyramine (30 lM) and par-
gyline (100 lM) (n = 4–5) at
3 months. (E,F) 5-hydroxy-
tryptamine (5-HT), 5-
hydroxyindoleacetic acid
(5-HIAA), norepinephrine (NE),
and dihydroxyphenylglycol
(DHPG) contents in cardiac
homogenates from NTg and
Tg mice assessed with high
performance liquid chroma-
tography (n= 5) at 1.5 months
(*p<0.05, **p<0.01, ***p<0.001,
xxxp<0.001 vs. indicated value).
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Table 1. Echocardiographic Measurements of Nontransgenic and Monoamine Oxidase-A Transgenic
Mice in Control Conditions and After Chronic Treatment with Clorgyline
Untreated Clorgyline-treated
NTg Tg-3 months Tg-5 months Tg-7 months NTg Tg-3 months Tg-5 months
No. of animals 16 11 12 4 5 5 5
DSWT, mm 0.67 – 0.01 0.64 – 0.01 0.67 – 0.01 0.68 – 0.04 0.63 – 0.01 0.63 – 0.02 0.66 – 0.01
DPWT, mm 0.68 – 0.02 0.64 – 0.01 0.69 – 0.02 0.76 – 0.09 0.67 – 0.02 0.65 – 0.02 0.64 – 0.01
LVEDD, mm 3.84 – 0.03 4.40 – 0.09a 4.50 – 0.06a 4.88 – 0.26a 3.93 – 0.16 4.02 – 0.17 4.16 – 0.09
LVESD, mm 2.73 – 0.05 3.40 – 0.01a 3.63 – 0.09a 4.08 – 0.39a 2.74 – 0.17 2.92 – 0.18 3.12 – 0.07b
FS (%) 28.9 – 1.0 22.5 – 1.1a 19.4 – 1.2a 16.5 – 3.5a 30.5 – 2.7 27.1 – 1.7 25.3 – 0.7b
HR, bpm 444.4– 12.9 475.0– 12.5 457.2– 17.0 484.8– 30.5 406.5– 20.7 453.0– 29.1 449.5– 8.9
ap< 0.05 in Tg versus NTg mice.
bp < 0.05 clorgyline-treated versus untreated age-matched Tg mice.
DSWT, diastolic septal wall thickness; DPWT, diastolic posterior wall thickness; LVEDD, left-ventricular end-diastolic diameter; LVESD,
left-ventricular end-systolic diameter; FS, fractional shortening; HR, heart rate assessment by echocardiography; Tg, transgenic; NTg,
nontransgenic.
FIG. 3. Evidence of cell
death in the hearts of MAO-
A Tg mice associated with
reactive cellular hypertro-
phy and fibrosis. (A) Histo-
logical characterization (·400)
of ventricular pathology by
hematoxylin-eosin (HE), pe-
riodic acid Schiff (PAS), and
Blue Masson’s Trichrome
staining in cardiac sections of
NTg, Tg 61, and clorgyline
(Clorg)-treated Tg 61 (Tg
61 + clorg) mice at 5 months.
Arrow indicates necrotic area.
(B) Quantification of cardio-
myocyte number per mm2,
cardiomyocyte diameter, and
collagen content on cardiac
sections (n= 5). (C) Evalua-
tion of troponin-I levels by
ELISA in plasma from NTg
and Tg 61 mice at 1.5 and 3
months (n= 4). (D) Quantifi-
cation of terminal deoxy-
nucleotidyl transferase dUTP
nick end labeling (TUNEL)-
positive apoptotic nuclei re-
lated to the total number of
nuclei in cardiac sections
from NTg and Tg 61 mice at
1.5 and 3 months (n = 4). (E)
Activated caspase-3 and (F)
p53 immunoblots on heart
homogenates from NTg and
Tg 61 at 1.5 months (*p< 0.05,
**p<0.01, ***p<0.001, xp<0.01,
xxp<0.001 vs. indicated value).
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anesthetized mice by an amperometric method. As shown in
Supplementary Figure S4B, concentration of H2O2 was signif-
icantly increased in ventricles from Tgmice at an early age (1.5
months) compared to NTg mice. Then, we analyzed the regu-
lation of antioxidant defenses in cardiac homogenates from
NTg and Tg mice. Interestingly, we found that the activity of
two enzymes specifically involved in H2O2 degradation, glu-
tathion peroxidase (GPX) and catalase (CAT), was modified in
Tg mice, while superoxide dismutase (Mn-SOD) activity re-
mained unchanged (Fig. 4B). To evaluate the participation of
oxidative stress in the onset of cardiac dysfunction associated
with MAO-A upregulation, we used a pharmacological
approach with N-acetyl-cystein (NAC), a ROS scavenger.
Chronic treatment with 1.5g/kg/day of NAC from 1 to 6
months improved antioxidant status since it was accompanied
by an increase in ventricle gluthatione reduced (GSH) content
(Supplementary Fig. S4C). As a consequence, NAC treatment
preserved cardiac function (FS) inTgmice at a level comparable
to NTg mice, and prevented cardiac dilatation (left-ventricular
end-systolic diameter [LVESD]) (Fig. 4C). Most interestingly,
cell loss was also prevented (Fig. 4C). Altogether, our results
provide evidence that chronic H2O2 generation by MAO-A
participates in progressive oxidative damage, cardiomyocyte
dropout, and deterioration of cardiac function in Tg mice.
Upregulation of MAO-A is associated
with mitochondrial damage in the heart
Mitochondrial dysfunction plays a major role in HF. Since
MAO-A is located in the outer membrane of mitochondria,
and mitochondrial DNA is oxidized in Tg mice, we hypoth-
esized that this organelle could be at particular risk for H2O2-
mediated injury. Expression profiling using microarrays
indicated a global downregulation of genes encoding mito-
chondrial proteins, and emphasized depressed energy me-
tabolism and oxidative phosphorylation in young Tg mice
accompanied by the downregulation of the PGC-1a pathway
(Fig. 5A, for a list of genes see Supplementary Tables S1
and S2). Therefore, we examinedmitochondrial ultrastructure
by electronic microscopy in Tg mice at the age of 1.5 months.
In NTg mice, mitochondria were normal with dense matrices
filled, homogeneous matrix granules, intact double mem-
brane, and tightly packed cristae (Fig. 5B, left panel). In con-
trast, Tg heart mitochondria tended to make aggregates and
were heterogeneous in size (Fig. 5B, right panel). In the same
cell, small and numerous mitochondria were observed, al-
ternating with normal or swelling mitochondria. The most
obvious changewas the appearance of electron-lucent areas in
mitochondrial matrix and concentric cristae. These morpho-
logical features indicated mitochondrial damage. Accord-
ingly, ATP content was decreased in myocardial samples
from 1.5-month-old Tg mice, suggesting early impairment in
mitochondrial bioenergetics (Fig. 5C). Finally, using real-time
reverse transcription–polymerase chain reaction (RT-PCR),
we confirmed that expression of PGC-1a, amaster regulator of
mitochondrial biogenesis, was significantly downregulated in
Tg mice at 1.5 months (Fig. 5D).
Upregulation of MAO-A sensitizes cardiomyocytes
to necrosis through p53 activation
To gain insight into the mechanism involved in MAO-A-
dependent cell necrosis, we developed an in vitro model of
MAO-A adenoviral vector (AdeMAO-A) transduction in
FIG. 4. Oxidative stress is
increased in hearts from
MAO-A overexpressing mice
and participates in the de-
velopment of dilated car-
diomyopathy. (A) 8-OH-dG
immuno-histochemistry on
cardiac sections from 5-month-
old NTg, Tg 61, and Clorg-
treated Tg 61 (Tg 61+ clorg)
mice (·400). Quantification of
8-OH-dG staining was ex-
pressed as percent of total area
(n=5). (B) Activity of antioxi-
dant enzymes glutathion per-
oxidase (GPX), catalase (CAT),
and superoxide dismutase
(Mn-SOD) in ventricles from 3-
month-old NTg and Tg 61
mice (n=5–6). (C) Fractional
shortening (FS), left-ventricular
end-systolic diameter (LVESD),
and cardiomyocyte number in
5-month-old NTg, Tg 61-un-
treated, and N-acetyl-cystein
(NAC)-treated Tg 61 (Tg61+
NAC) mice (n=6) (*p<0.05,
**p<0.01, ***p<0.001, xp<0.05,
xxp<0.01 vs. indicated value).
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neonatal cardiomyocytes. AdeMAO-A transduction (multi-
plicity of infection [MOI] 5) induced a significant increase in
MAO-A activity in cardiomyocytes (Fig. 6A). Interestingly,
application of NE (24 h) induced cardiomyocyte necrosis only
in cells transduced with AdeMAO-A, as demonstrated by
lactate dehydrogenase (LDH) release (Fig. 6B). Thus, as ob-
served in Tg mice, in the presence of a constant substrate
concentration, an increase in MAO-A activity sensitizes car-
diomyocytes to necrosis. We confirmed this finding with
tyramine, another MAO substrate devoid of membrane re-
ceptors in the mammalian heart. Tyramine application for
24 h promoted necrosis in cardiomyocytes transduced with
AdeMAO-A (MOI 5), which was prevented by clorgyline and
the antioxidants NAC and Trolox (Fig. 6C). Tyramine treat-
ment did not modify MAO-A expression (Supplementary
Fig. S5A). Oxidation of the fluorescent probe DCFDA
was evidenced 2h after tyramine application, only inAde-MAO-
A-transduced cardiomyocytes, and was inhibited with clorgy-
line, NAC, and Trolox (Fig. 6D). In addition, tyramine applica-
tion decreased GSH content in Ade-MAO-A-transduced
cardiomyocytes but not in NAC-treated cardiomyocytes (Sup-
plementary Fig. S5B). Aswe observed a significant accumulation
of p53 in Tg hearts compared to NTg (Fig. 3F), we hypothesized
that this protein could play an important role in MAO-A-
dependent cell necrosis. We examined the kinetic of p53 activa-
tion in AdeMAO-A-transduced cardiomyocytes in the presence
of tyramine. Interestingly, tyramine treatment induced a rapid
increase in phospho(ser15)-p53 (Fig. 6E), which was dependent
on ROS generation since it was prevented in the presence of
NAC or Trolox (Fig. 6F). This increase in phospho(ser15)-p53
was not observed in untransduced cardiomyocytes treated with
tyramine (Supplementary Fig. S5C). Expression of total p53 was
also significantly increased after 6h of tyramine treatment (Fig.
6E). Therefore, we testedwhether p53 activation played a role in
MAO-A-dependent necrosis by an siRNA approach. As shown
in Figure 6G, p53 siRNA transfection inhibited p53 protein
expression at 48 and 72h compared to Scr-transfected cells.
As a consequence, LDH release was significantly reduced in
p53-silenced cardiomyocytes compared to Scr (Fig. 6G). Tyr-
amine-induced LDH release was also significantly reduced in
cardiomyocytes treated with a pharmacological p53 inhibitor,
pifithrin-a, compared to vehicle-treated cardiomyocytes (Fig.
FIG. 5. MAO-A overexpression in-
duces mitochondrial injury. (A) Gen-
eset Enrichment Analysis for
differentially expressed genes by mi-
croarray in Tg compared to NTg mice
(2 months). Common themes were
defined among the various over-
lapping and unique gene sets. Blue
blocks and red blocks represent highly
enriched in category among the vari-
ous downregulated or upregulated
genes, respectively. (B) Representative
electron micrographs of ventricles
from 1.5-month-old NTg and Tg 61
mice (· 10,000). Cardiomyocytes from
Tg mice show electron-lucent areas in
mitochondrial matrix (arrows) or con-
centric cristae (asterisk). (C) ATP con-
centrations in ventricle homogenates at
1.5 months (n = 4). (D) Real-time re-
verse transcription–polymerase chain
reaction (RT-PCR) expression of per-
oxisome proliferator-activated recep-
tor-c coactivator-1a (PGC-1a) mRNA
at 1.5 months (n = 5) (*p < 0.05,
**p < 0.01 vs. indicated value).
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6H). In conclusion, our data demonstrate for the first time that
p53 activation plays a major role in MAO-A-mediated cardio-
myocyte necrosis.
Mitochondrial damage and PGC-1a downregulation
are key events in MAO-A-dependent cardiomyocyte
necrosis, which are both dependent on p53 activation
Early mitochondrial impairment was observed in MAO-A
Tgmice. Thus, we asked whether MAO-A activation could be
responsible for mitochondrial damage in vitro. As shown in
Figure 7A, as soon as 4 h after tyramine application, mito-
chondrial ultrastructure was severely impaired in AdeMAO-
A-transduced cardiomyocytes but not in untransduced car-
diomyocytes (Supplementary Fig. S5D). These ultrastructural
alterations fitted with ATP depletion and PGC-1a down-
regulation, indicating a rapid decline in cell metabolic func-
tion in Ade-Mao-A-transduced cardiomyocytes (Fig. 7C, E).
Therefore, we asked whether p53 contributed to MAO-A-
induced mitochondrial damage. Most interestingly, p53
silencing attenuated mitochondrial ultrastructural defects
(Fig. 7A, B) and PGC-1a downregulation (Fig. 7D) compared
to Scr-transfected cells. This is consistent with recent data that
identified p53 as an important and direct repressor of PGC-1a
in the heart, an event that participates in the functional decline
of cardiac function during aging (34). Finally, we evaluated
FIG. 6. p53 mediates MAO-A-
dependent cardiomyocyte necrosis.
(A–D) Neonatal cardiomyocytes were
untransduced (multiplicity of infection
[MOI] 0) or transduced with Ade-
MAO-A at MOI 5. (A) Quantification
of MAO-A activity by luminescence
(n = 3). (B) Lactate dehydrogenase
(LDH) release after treatment with
50lM NE for 24 h (n = 8–9). (C) LDH
release in response to 500lM tyramine
for 24 h in the presence of 10lM Clorg
(Tyr + clorg), 5mM NAC (Tyr +NAC),
or 1mM Trolox (Tyr +Trolox), when
indicated (n= 4–5). (D) Reactive oxy-
gen species generation with DCFDA
probe in response to 500lM tyramine
for 2 h in the presence of NAC (5mM),
Clorg (10 lM), or 1mM Trolox (Tyr +
Trolox), when indicated (n = 9) in un-
transduced (MOI 0) or AdeMAO-A-
transduced (MOI 5) cells. (E,F) Analysis
of total or phosphor(ser15)-p53 lev-
els by immunoblot in AdeMAO-A-
transduced neonatal cardiomyocytes
(MOI 5) stimulated with 500lM tyra-
mine for the indicated time in the
presence of NAC or Trolox, when in-
dicated (n= 3–5). GAPDH was used as
a loading control. (G) LDH release in
AdeMAO-A-transduced cardiomyo-
cytes (MOI 5) transfected with Scr or
p53 siRNA for 48 h, and stimulated
with 500 lM tyramine for 24 h (n= 7).
Immunoblot illustrates silencing of p53
protein at 48 and 72 h after siRNA
transfection. (H) LDH release in
AdeMAO-A-transduced cardiomyocytes
(MOI 5) stimulated with 500lM tyra-
mine for 24 h in the presence of 20 lM
pifithrin, when indicated (n = 6–8)
*p< 0.05, **p< 0.01, ***p< 0.001, xp< 0.05,
xxp< 0.01 versus indicated values or Ct.
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the contribution of H2O2 and oxidative stress in the regulation
of PGC-1a. We found that treatment with antioxidants NAC
or Trolox prevented PGC-1a mRNA diminution in response
to tyramine in MAO-A-overexpressing cardiomyocytes (Fig.
7E). Thus, our results demonstrate that an increase inMAO-A
activity sensitizes cardiomyocytes to mitochondrial damage,
metabolic decline, and cell necrosis through the generation of
oxidative stress. In addition, p53-dependent repression of
PGC-1a in cardiomyocytes constitutes an important step in
MAO-A-dependent necrosis (Fig. 7F).
Discussion
In the present study, we demonstrate for the first time that a
chronic increase in MAO-A engenders mitochondrial oxida-
tive damage, PGC-1a downregulation, myocyte necrosis, and
HF. Importantly, we report that p53 acts as a major down-
stream effector of MAO-A-dependent mitochondrial injury,
PGC-1a downregulation, and myocyte necrosis.
A deleterious role for MAO-A/H2O2 axis has been well
documented in acute situations such as cardiac ischemia-
reperfusion. In those studies, pharmacological or genetic
inactivation of MAO-A prevented postreperfusion cardiac
oxidative stress and cardiomyocyte death (6, 30). However,
until now, the importance of MAO-A/H2O2 axis in chronic
situations such as HF or aging remained poorly understood.
Thus, our observation that enhanced MAO-A activity per se is
sufficient to trigger deleterious effects in the heart represents a
new finding, particularly relevant in cardiac diseases where
MAO-A upregulation appears to be frequently observed (14,
FIG. 7. p53 mediates mitochondrial
injury and PGC-1a repression in-
duced by MAO-A activation in neo-
natal cardiomyocytes transduced
with AdeMAO-A (MOI 5). (A) Re-
presentative electron micrographs of
cardiomyocytes transfected with Scr
or p53 siRNA and stimulated with
tyramine for 4 h (Tyr) (· 35,000).
Tyramine-treated Scr-transfected car-
diomyocytes display damaged mito-
chondria (arrows), which are quantified
in (B). (C) Kinetics of ATP content in
AdeMAO-A-transduced cardiomyo-
cytes (MOI 5) treated with tyramine
(n = 3) compared to untransduced
(MOI 0) cells. (D) PGC-1a expression
by real-time RT-PCR in cardiomyo-
cytes transfected with Scr or p53 siR-
NA and stimulated with tyramine for
4 h (n = 8). (E) PGC-1a expression by
real-time RT-PCR in untransduced or
AdeMAO-A-transduced cardiomyo-
cytes stimulated with tyramine for 4 h
in the presence of NAC (5mM) or
Trolox (1mM) (n = 4). (F) Schematic
representation of the MAO-A-induced
necrosis signaling pathway in cardio-
myocytes. *p< 0.05, **p < 0.01, ***p <
0.001, xp< 0.05, versus indicated values.
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16). We found that MAO-A activity was increased in rat heart
during pressure overload-induced hypertrophy and failure,
and during cardiac aging. At present, the rationale for MAO-
A upregulation during cardiac stress remains unknown.
Sympathetic activation and NE spillover are major features
associated with cardiac aging and failure (9, 15). In addition,
whole-blood 5-HT levels increase in failing human hearts (28).
Therefore, MAO-A upregulation might be an adaptative
mechanism to increased levels of substrates, as previously
demonstrated in rat mesangial cells (31). However, on the
long-term, a chronic increase in 5-HT and catecholamines
metabolism by cardiac MAO-A could induce oxidative stress
and cardiomyocyte toxicity. Understanding the mechanisms
of MAO-A upregulation in the heart seems of major interest
and will need to be elucidated in future studies.
In our model, overexpression of MAO-A in mice led to a
decrease in cardiac NE and 5-HT, together with an increase in
their respective MAO metabolites DHPG and 5-HIAA. This
observation is consistent with previous studies showing an
accumulation of 5-HT and/or NE levels in the heart after
pharmacological or genetic inhibition of MAO-A (14, 19).
Monoamine neurotransmitters have major functional impli-
cations in the heart, especially in the modulation of cardiac
inotropy and compensatory hypertrophy (14, 19). Thus, it is
possible that enhanced catabolism of 5-HT and NE in Tg mice
contribute to heart dysfunction. On the other hand, mono-
amine oxidation by MAO-A leads to the generation of H2O2,
but also aldehyde intermediates, which are rapidly trans-
formed to their corresponding alcohol DHPG and 5-HIAA.
Aldehydes are highly reactive species that are toxic for bio-
logical systems andmay contribute to cell death together with
H2O2 (22). Although we could not rule out a role for substrate
depletion or aldehyde generation in cardiac dysfunction, we
provided evidence that oxidative stress played a key role in
cardiomyocyte dropout and HF in Tg mice. First, using an
original approach of direct real-time H2O2 detection in mice
heart, we showed that Tg mice were constantly exposed to
high H2O2 cardiac level at an early age. This observation
correlated with the appearance of DNA oxidative damage.
Second, chronic treatment with an antioxidant (NAC) in-
creasedGSH content and prevented cardiomyocyte death and
cardiac failure in Tg mice. Altogether, our results put forward
that MAO-A upregulation represents an endogenous system
of chronic ROS generation leading to heart dysfunction. This
is in accordance with a recent study demonstrating a protec-
tive effect of MAO-A inhibition on cardiac oxidative stress
and failure during pressure overload (14). Interestingly, we
found that the activity of two enzymes involved in H2O2
degradation, GPX and CAT, were modified in opposite di-
rections in MAO-A Tg mice. GPX mRNA (not shown) and
activity were upregulated, whereas CAT mRNA (not shown)
and activity were downregulated. Upregulation of GPX by
oxidative stress has been reported in different cell types (21)
andmay involve the activation of transcription factors such as
NFkB or p53 (13), the latter being increased in Tgmice. On the
other hand, CAT gene expression has previously been dem-
onstrated to be downregulated by chronic oxidative stress (25,
40). One potential mechanism could involve hypermethyla-
tion of the CAT promoter by H2O2, which leads to drastic
reduction in CAT protein expression (25). Alternatively, in-
hibition of CAT could be related to the downregulation of
PGC-1a in Tg mice, which is a co-factor necessary to maintain
normal expression of antioxidant genes in coordination with
FoxO transcription factors (29).
When examining MAO-A-induced cardiomyocyte death,
apoptotic nuclei were barely detectable in young Tg mice.
Considering that caspase-3 was not activated in Tg hearts, we
concluded that such a level of apoptosis was insufficient to
explain themajor cardiomyocyte loss observed in Tgmice. On
the other hand, we found that necrosis was strongly enhanced
in Tg hearts, as assessed by histological examinations and
plasma troponin-I measurement. Moreover, MAO-A over-
expression in vitro rendered the cardiomyocytes more vul-
nerable to necrosis in the presence of NE and tyramine.
According to its concentration, H2O2 has been demonstrated
to induce either apoptosis or necrosis in cardiomyocytes (18).
In addition, human aged cells with accumulative oxidative
damages are more sensitive to necrosis (26). Therefore, MAO-
A upregulation during cardiac failure or aging could sensitize
cardiomyocytes to necrosis. This observation is interesting
since, after being neglected for a while, necrosis is now rec-
ognized as a major way of cell death during chronic HF (27).
Hence, elucidating necrotic signaling cascades in the heart
seems of major interest. Here, we provide evidence that p53
accumulates in the hearts of Tg mice and can be rapidly ac-
tivated by tyramine in vitro. Both pharmacological and siRNA
approaches demonstrated its involvement in cardiomyocyte
necrosis induced by MAO-A. The identification of p53 as a
mediator of cardiomyocyte necrosis in response to oxidative
stress is consistent with accumulating evidence demonstrat-
ing an important role of p53 in HF (23, 36). In addition, apart
from being a well-known pro-apoptotic factor, p53 has been
demonstrated to participate in cell necrosis induced by DNA
damage or TNFa (38, 41).
Based on our observations, overexpression of MAO-A
in vitro and in vivo was associated with mitochondrial ultra-
structural defects, ATP depletion, and PGC-1a down-
regulation. In vitro, p53 silencing prevented tyramine-induced
mitochondrial damage and PGC-1a downregulation, indi-
cating that p53 activation played a key role in amplifying
mitochondrial injury in response to MAO-A/H2O2. Interest-
ingly, such a link between mitochondrial oxidative damage
and p53 activation has been recently observed in a model of
HF induced by doxorubicin (39). Downregulation of PGC-1a
in our model is interesting since it has been reported to con-
tribute to the maladaptive energetic profile of failing hearts
(32). PGC-1a downregulation could alter mitochondrial bio-
genesis/bioenergetics (3) or lead to a decrease in antioxidant
enzymes, as previously described (20).
In conclusion, our results demonstrate that enhancing
MAO-A expression, as observed in different models of car-
diomyopathy, induces the activation of p53, which acts as a
repressor of PGC-1a expression and contributes to bioener-
getic defects and mitochondrial damage leading to cardio-
myocyte necrosis (Fig. 7F). These findings put forward that an
increase in cardiac MAO-A could play a major role in the
progression of HF, and proposeMAO-A as a promising target
for the prevention of cardiomyocyte death in chronic diseases.
Materials and Methods
Generation of Tg mice
The cDNA encoding rat MAO-A (genbank NM_033653)
provided by Akio Ito (Kyushu University, Japan) was
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subcloned into the full-length mouse a-MHC promoter.
Briefly, a 2060-bp cDNA, including 6 bp of the 5¢ and 474 bp of
the 3¢ flanking sequences, was subcloned into the SalI site of
the polylinker of the a-MHC promoter construct (12). The
resulting recombinant plasmid, paMHC-MAO-A, was con-
firmed by restriction mapping and nucleotide sequencing. A
linear 8000-bp DNA fragment was microinjected into fertil-
ized eggs at the ‘‘Institut Clinique de la Souris’’ (Strasbourg,
France). Offsprings were genotyped and founders were bred
with C57BL6/J mice to establish stable Tg mice. Mice were
housed in a pathogen-free facility and handled in accordance
with the principles and procedures outlined in Council Di-
rective 86/609/EEC. For all experiments, littermates were
used as controls.
Assays of MAO activity
MAO-A activities in cardiac tissues were performed as
previously described (19). For in vitro assays, 5lg of cellular
lysates was incubated with 20 lM MAO-A substrate (MAO-
Glo Assay kit; Promega) for 20min at 37C and nonspecific
activity was defined in the presence of clorgyline.
Primary cultures of cardiomyocytes
Adult ventricular myocytes were obtained from hearts of
male Sprague-Dawley rats at the ages of 2, 12, and 24 months
with retrograde perfusion, as previously described (6). For
neonatal cardiomyocytes, hearts of 2–3-day-old Sprague-
Dawley rats were dissociated with collagenase type II, 0.1%
(Biovalley), as previously described (30). Myocyte enrichment
was performed by centrifugation through a discontinuous
Percoll gradient and resultant suspension of myocytes was
plated onto gelatin-coated culture dishes. About 24 h after
adenovirus transduction, the medium was replaced with the
Ham-F12 medium supplemented with dialyzed-FCS 3% and
inhibitors (clorgyline, NAC, pifithrin-a), when indicated.
Tyramine was added 2h later for the indicated time. The se-
lected siRNA for p53 is an ON-TARGET plus SMART pool
siRNA (Dharmacon). SiRNAs were transfected 24 h before
AdeMAO-A adenovirus transduction, using the Dharmafect
reagent according to the manufacturer’s recommendations.
Western blot
Ventricular homogenates and cardiomyocyte extracts were
electrophoresed and transferred as described (19). Mem-
branes were incubated with anti-MAO-A, anti-GAPDH anti-
bodies (Santa Cruz Biotechnology) or anti-caspase-3, anti-p53,
anti-phospho-p53 antibodies (Cell Signaling).
Immunofluorescence
Frozen cardiac sections were fixed with PFA 3% for 15min
and neutralized with glycine 100mM. After permeabilization
with Triton 0.5%, heart sections were incubated first with
MAO-A antibody overnight at 4C, and cytochrome c oxidase
IV (CoxIV) antibody (Santa Cruz Biotechnology) at room
temperature for 1 h. After washing, sections were incu-
bated for 1 h at room temperature with Oregon Green 488-
conjugated goat antirabbit or Alexa 594-conjugated goat
antimouse antibodies (Invitrogen). Images were acquired
using a DM600 microscope (Leica) fitted with a Roper
COOLsnap ES CCD camera. Images were denoized using the
Nearest Neighbours approach of the 2D Deconvolution setup
of Metamorph software (Filter size: 2; Scaling Factor: 0.5;
Result Scale: 2).
Electron microscopy
LVs of mice were cut in cubes of 1mm3 and placed in
glutaraldehyde 2.5%. Semi-thin (1 lm) sections were stained
with toluidine blue. Trimmed ultra-thin sections (600 A˚) were
stained with uranyl acetate and lead citrate. Sections were
examined under a transmission electron microscopy (Hitashi
5HU12A).
Mitochondrial H2O2 production
Cardiac mitochondria were isolated using the procedure of
Gomez et al. (11). Total H2O2 production was measured using
a fluorimeter F-2500 (Hitachi) and a fluorescent probeAmplex
Red (10lM) in the presence of 0.6U/ml horseradish per-
oxidase (excitation and emission wavelengths set to 530 and
590 nm, respectively).
Assays of 5-HT, 5-HIAA, NE, and DHPG
Snap-frozen ventricular tissues were homogeneously
grinded in 1.5mlwater. Assays for 5-HT, 5-HIAA (2), andNE,
DHPG (5) were performed using two different HPLC meth-
ods with coulometric detection applied to tissues. For 5-HT
and 5-HIAA, determinations were made without extraction
on the centrifugated supernatants after deproteinization of
the aqueous mixture using HClO4 0.1 M and ascorbic acid
3.10- 4 M. For NE and DHPG determinations, 500ll samples
of the aqueous centrifugated mixture were extracted using
acid-washed alumina columns.
Echocardiography
Animals were anesthetized with 2% isoflurane and exam-
ined with noninvasive echocardiography (echocardiograph
Vivid 7 ultrasound; GE). Cardiac ventricular dimensions
were measured on M-mode images at least five times for the
number of animals indicated.
Histological analysis
Ventricles were incubated in the Carnoy’s fixative solution
(ethanol 60%, chloroform 30%, and acetic acid 10%), embed-
ded in paraffin, and transversally sectioned. Five-lm tissue
sectionswere stainedwithH&E,Masson’s Trichrome, or PAS.
Fibrosis was measured as positively stained area with Mas-
son’s Trichrome (green), and expressed as percent of total
area, using a computer-based morphometric analysis (Nis-
element; Nikon). Cardiomyocyte diameter was evaluated af-
ter coloration with PAS (250–300 cells counted per heart) on
LV. Number of cardiomyocytes per total myocardial area was
measured using manual-counting function of the analysis
software in three consecutive areas of the LV. For 8-OH-dG (a
marker of nuclear and mitochondrial DNA oxidation) im-
munohistochemistry, antigen retrieval was performed using
citrate solution (sodium citrate 1M, citric acid 1M, pH 6.0) at
97C during 40min. After washing with deionized water,
endogenous peroxidase activity was blocked with H2O2 30%
for 10min. 8-OH-dG mouse monoclonal antibody (1:200;
AbCys) was incubated for 2 h at 37C and secondary antibody
for 30min at room temperature. Slides were washed and
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incubated with 1:50 DAB in substrate buffer for 5min, and
then counterstained with 1:4 Mayer’s hematoxylin. Positively
stained area was quantified using a computer-based mor-
phometric analysis (Nis-element; Nikon) and calculated as
percent of total area. Apoptosis was evaluated by TUNEL
staining on cardiac sections as previously described (6).
Real-time RT-PCR
Extraction of RNA from cardiac ventricles was performed
using column affinity purification (Qiagen). cDNAs were
synthesized using the superscript II RT-PCR system (In-
vitrogen) with random hexamers. Real-time PCR was per-
formed on a StepOnePlus system (Applied Biosystem) in
96-well plates with specific primers and SYBR green mix
(Eurogentec). The primers were as followed—mouse PGC-1a-
F: ACGGTTTACATGAACACAGCTGC, mouse PGC-1a-R:
CTTGTTCGTTCTGTTCAGGTGC, rat PGC-1a-F: CACCAAA
CCCACAGAGAACAG, and rat PGC-1a-R: GCAGTTCCAG
AGAGTTCCACA.
Plasmatic troponin
Plasmatic troponin-I was detected using an ELISA kit ac-
cording to the manufacturer’s instructions (Life Diagnostic).
Briefly, plasma samples were incubated for 1 h at room tem-
perature with an HRP-conjugated anti-cTn-I antibody in mi-
crotiter wells. After extensivewash, HRP substrate was added
in each well for 20min at room temperature and the reaction
stopped with HCl 1 M. Absorbance was measured at 450 nm
and plasmatic cTn-I concentration was determined using cTn-
I standards.
Antioxidant enzyme activities
CAT activity was determined by the procedure of Aebi (1).
For GPX and Mn-SOD, activities were evaluated as previ-
ously described (35).
Microarray analysis
Total RNAwas prepared as described above. The quality of
samples was verified with Agilent Bioanalyzer 6000 (Agilent
Technologies). Hybridization of RNA was done on Agilent
Mouse Genome CGH 44K chip at the Genotoul Biopuces
Plate-forme). Raw data (median values) were normalized and
processed using the R statistical software and the limma
package for microarrays. Weights were attributed to flag bad
data points and the remaining values were Loess-normalized
within arrays and quantile-normalized between arrays. Lim-
ma was used to generate log2 ratios (coefficents) and p-values
(using eBayes) in order to select genes with differential ex-
pression between groups that were alsowell behaved in terms
of expression within each individual group. Using a log2 ratio
of 0.5 (fold-change 1.4) and a p-value cutoff of 0.005, genes
were selected for analysis. GeneSet Enrichment Analysis for
categorical feature overrepresentation in each gene list (up-
regulated or downregulated) was performed using Toppgene
(http://toppgene.cchmc.org/). For each enrichedGeneset, the
enrichment p-value for nonrandom list intersection (using
Bonferroni p-value correction) was converted to a significance
score [S = - log (pval)] and a matrix was constructed with
colors scaled to significance scores. Common themes were
defined among the various overlapping and unique Genesets.
ATP measurement
Snap-frozen cardiac samples (30mg) were homogenized in
500-ll ice-cold perchloric acid (10% v/v), sited on ice for
10min, and centrifuged at 14,000 rpm for 10min at 4C. Su-
pernatants were neutralized with KOH 2.5M and centrifuged
at 4500 rpm for 5min. Supernatants from cardiac sample ex-
traction or cell lysates were assayed for ATP assay kit (Bio-
luminescence assay kit HS II; Roche).
Adenoviral constructs
Replication-deficient (DE1, E3), adenoviral vector-expressing,
MAO-A-coding region (1.9 kb) under the control of the
CMV promoter was constructed with the AdEasy System
(Qbiogen). Replication-defective MAO-A adenovirus (Ade-
MAO-A) was generated by transfection of 293A cells with a
single isolate of recombinant adenoviral vector, expanded,
and purified. Viral titers were initially determined by optical
absorbance at 260 nm. Infections were done at a certain MOI
based on this definition; for example, 1· 106 bav/1· 106
cells=MOI 1.
Intracellular ROS measurement
Generation of ROS in cardiomyocytes was evaluated using
DCFDA probe as previously described (6).
LDH release assay
For quantitative assessment of cardiomyocyte necrosis,
LDH release in culture medium was measured using LDH-
cytotoxicity Assay Kit according to the manufacturer’s in-
structions (Biovision).
Statistical analysis
Results are expressed as mean– SEM. Experimental groups
were compared using Student’s t-test or one-way analysis of
variance, as appropriate. A value of p< 0.05 was considered
significant.
Acknowledgments
This work was supported by grants from INSERM,
Agence Nationale pour la Recherche (ANR), Fondation pour
la Recherche Medicale (FRM), Mouse Clinical Institute
(MCI) in Strasbourg, and Re´gionMidi-Pyre´ne´es. We thank J.
S. Iacovoni for bioinformatics. We thank A. Colom (INSERM
UMR1048) and E. Couture-Lepetit (INSERM U886) for
technological assistance. We thank D. Langin and F. Le-
zoualc’h (INSERM UMR1048) for critical reading of the
manuscript.
Author Disclosure Statement
No competing financial interests exist.
References
1. Aebi H. Catalase in vitro. Methods Enzymol 105: 121–126,
1984.
2. Alvarez JC, Bothua D, Collignon I, Advenier C, and Spreux-
Varoquaux O. Simultaneous measurement of dopamine,
serotonin, their metabolites and tryptophan in mouse brain
homogenates by high-performance liquid chromatography
16 VILLENEUVE ET AL.
with dual coulometric detection. Biomed Chromatogr 13: 293–
298, 1999.
3. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ah-
mad F, Matsui T, Chin S, Wu PH, Rybkin, II, Shelton JM,
Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig
A, Ingwall JS, and Spiegelman BM. Transcriptional coacti-
vator PGC-1 alpha controls the energy state and contractile
function of cardiac muscle. Cell Metab 1: 259–271, 2005.
4. Barja G and Herrero A. Oxidative damage to mitochondrial
DNA is inversely related to maximum life span in the heart
and brain of mammals. FASEB J 14: 312–318, 2000.
5. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay
JM, and Puech AJ. Monoamine oxidase A and B activities in
heavy smokers. Biol Psychiatry 38: 756–761, 1995.
6. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D,
Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq N,
and Parini A. Oxidative stress by monoamine oxidase me-
diates receptor-independent cardiomyocyte apoptosis by
serotonin and postischemic myocardial injury. Circulation
112: 3297–3305, 2005.
7. De Sousa E, Veksler V, Minajeva A, Kaasik A, Mateo P,
Mayoux E, Hoerter J, Bigard X, Serrurier B, and Ventura-
Clapier R. Subcellular creatine kinase alterations. Implica-
tions in heart failure. Circ Res 85: 68–76, 1999.
8. Dorn GW, 2nd. Apoptotic and non-apoptotic programmed
cardiomyocyte death in ventricular remodelling. Cardiovasc
Res 81: 465–473, 2009.
9. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lam-
bert G, Kaye DM, Kopin IJ, Goldstein DS, and Esler MD.
Cardiac sympathetic nerve function in congestive heart
failure. Circulation 93: 1667–1676, 1996.
10. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart
failure. J Clin Invest 115: 500–508, 2005.
11. Gomez L, Paillard M, Thibault H, Derumeaux G, and Ovize
M. Inhibition of GSK3beta by postconditioning is required
to prevent opening of the mitochondrial permeability
transition pore during reperfusion. Circulation 117: 2761–
2768, 2008.
12. Gulick J, Subramaniam A, Neumann J, and Robbins J. Iso-
lation and characterization of the mouse cardiac myosin
heavy chain genes. J Biol Chem 266: 9180–9185, 1991.
13. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I,
Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth
LJ, Moake M, Nagashima M, Forrester KS, and Harris CC.
p53-induced up-regulation of MnSOD and GPx but not
catalase increases oxidative stress and apoptosis. Cancer Res
64: 2350–2356, 2004.
14. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW,
Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak
K, Kass DA, Di Lisa F, and Paolocci N. Monoamine oxidase
A-mediated enhanced catabolism of norepinephrine con-
tributes to adverse remodeling and pump failure in hearts
with pressure overload. Circ Res 106: 193–202, 2010.
15. Kaye D and Esler M. Sympathetic neuronal regulation of the
heart in aging and heart failure. Cardiovasc Res 66: 256–264,
2005.
16. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, and
Kang PM. Genetic expression profiles during physiological
and pathological cardiac hypertrophy and heart failure in
rats. Physiol Genomics 21: 34–42, 2005.
17. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K,
Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA,
Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Ta-
nokura M, Weindruch R, Leeuwenburgh C, and Prolla TA.
Mitochondrial DNA mutations, oxidative stress, and apo-
ptosis in mammalian aging. Science 309: 481–484, 2005.
18. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, and
Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype
via concentration-dependent activation of distinct kinase
pathways. J Mol Cell Cardiol 35: 615–621, 2003.
19. Lairez O, Calise D, Bianchi P, Ordener C, Spreux-Varoquaux
O, Guilbeau-Frugier C, Escourrou G, Seif I, Roncalli J, Piz-
zinat N, Galinier M, Parini A, and Mialet-Perez J. Genetic
deletion of MAO-A promotes serotonin-dependent ventric-
ular hypertrophy by pressure overload. J Mol Cell Cardiol 46:
587–595, 2009.
20. Lu Z, Xu X, Hu X, Fassett J, Zhu G, Tao Y, Li J, Huang Y,
Zhang P, Zhao B, and Chen Y. PGC-1 alpha regulates ex-
pression of myocardial mitochondrial antioxidants and
myocardial oxidative stress after chronic systolic overload.
Antioxid Redox Signal 13: 1011–1022, 2010.
21. Lubos E, Loscalzo J, and Handy DE. Glutathione peroxi-
dase-1 in health and disease: from molecular mechanisms to
therapeutic opportunities. Antioxid Redox Signal 15: 1957–
1997, 2011.
22. Marchitti SA, Deitrich RA, and Vasiliou V. Neurotoxicity
and metabolism of the catecholamine-derived 3,4-
dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylgly-
colaldehyde: the role of aldehyde dehydrogenase. Pharmacol
Rev 59: 125–150, 2007.
23. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T,
Sunagawa K, Kinugawa S, and Tsutsui H. Targeted deletion
of p53 prevents cardiac rupture after myocardial infarction
in mice. Cardiovasc Res 70: 457–465, 2006.
24. Maurel A, Hernandez C, Kunduzova O, Bompart G, Cam-
bon C, Parini A, and Frances B. Age-dependent increase
in hydrogen peroxide production by cardiac monoamine
oxidase A in rats. Am J Physiol Heart Circ Physiol 284: H1460–
H1467, 2003.
25. Min JY, Lim SO, and Jung G. Downregulation of catalase by
reactive oxygen species via hypermethylation of CpG island
II on the catalase promoter. FEBS Lett 584: 2427–2432.
26. Miyoshi N, Oubrahim H, Chock PB, and Stadtman ER. Age-
dependent cell death and the role of ATP in hydrogen per-
oxide-induced apoptosis and necrosis. Proc Natl Acad Sci U S
A 103: 1727–1731, 2006.
27. Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X,
Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser
SR, and Molkentin JD. Ca2 + - and mitochondrial-dependent
cardiomyocyte necrosis as a primary mediator of heart fail-
ure. J Clin Invest 117: 2431–2444, 2007.
28. Nigmatullina RR, Kirillova VV, Jourjikiya RK, Mukhame-
dyarov MA, Kudrin VS, Klodt PM, and Palotas A. Disrupted
serotonergic and sympathoadrenal systems in patients with
chronic heart failure may serve as new therapeutic targets
and novel biomarkers to assess severity, progression and
response to treatment. Cardiology 113: 277–286, 2009.
29. Olmos Y, Valle I, Borniquel S, Tierrez A, Soria E, Lamas S,
and Monsalve M. Mutual dependence of Foxo3a and PGC-
1alpha in the induction of oxidative stress genes. J Biol Chem
284: 14476–14484, 2009.
30. Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas
MH, Leducq N, Seif I, Parini A, and Cuvillier O. Oxidative
stress-dependent sphingosine kinase-1 inhibition mediates
monoamine oxidase A-associated cardiac cell apoptosis. Circ
Res 100: 41–49, 2007.
31. Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C,
Bompart G, and Parini A. Substrate-dependent regulation of
MAO-A AND CARDIAC OXIDATIVE DAMAGE 17
MAO-A in rat mesangial cells: involvement of dopamine
D2-like receptors. Am J Physiol Renal Physiol 284: F167–F174,
2003.
32. Rimbaud S, Garnier A, and Ventura-Clapier R. Mitochon-
drial biogenesis in cardiac pathophysiology. Pharmacol Rep
61: 131–138, 2009.
33. Rosca MG and Hoppel CL. Mitochondria in heart failure.
Cardiovasc Res 88: 40–50, 2010.
34. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M,
Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon
G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M,
Martin ES, Heffernan TP, Protopopov A, Ivanova E, Maho-
ney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R,
Mulligan R, Shirihai OS, Chin L, and DePinho RA. Telomere
dysfunction induces metabolic and mitochondrial compro-
mise. Nature 470: 359–365, 2011.
35. Sebastiani M, Giordano C, Nediani C, Travaglini C, Borchi
E, Zani M, Feccia M, Mancini M, Petrozza V, Cossarizza A,
Gallo P, Taylor RW, and d’Amati G. Induction of mitochon-
drial biogenesis is a maladaptive mechanism in mitochondrial
cardiomyopathies. J Am Coll Cardiol 50: 1362–1369, 2007.
36. Toko H, Takahashi H, Kayama Y, Oka T, Minamino T,
Okada S, Morimoto S, Zhan DY, Terasaki F, Anderson ME,
Inoue M, Yao A, Nagai R, Kitaura Y, Sasaguri T, and Ko-
muro I. Ca2 +/calmodulin-dependent kinase IIdelta causes
heart failure by accumulation of p53 in dilated cardiomy-
opathy. Circulation 122: 891–899, 2010.
37. Tsutsui H, Kinugawa S, and Matsushima S. Mitochondrial
oxidative stress and dysfunction in myocardial remodelling.
Cardiovasc Res 81: 449–456, 2009.
38. Tu HC, Ren D, Wang GX, Chen DY, Westergard TD, Kim H,
Sasagawa S, Hsieh JJ, and Cheng EH. The p53-cathepsin axis
cooperates with ROS to activate programmed necrotic death
upon DNA damage. Proc Natl Acad Sci U S A 106: 1093–1098,
2009.
39. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plab-
plueng CD, Oberley T, Jungsuwadee P, Van Remmen H,
Vore M, and St Clair DK. p53 Regulates oxidative stress-
mediated retrograde signaling: a novel mechanism for che-
motherapy-induced cardiac injury. PLoS One 6: e18005, 2011.
40. Venkatesan B, Mahimainathan L, Das F, Ghosh-Choudhury
N, and Ghosh Choudhury G. Downregulation of catalase by
reactive oxygen species via PI 3 kinase/Akt signaling in
mesangial cells. J Cell Physiol 211: 457–467, 2007.
41. Waters FJ, Shavlakadze T, McIldowie MJ, Piggott MJ, and
Grounds MD. Use of pifithrin to inhibit p53-mediated sig-
nalling of TNF in dystrophic muscles of mdx mice. Mol Cell
Biochem 337: 119–131, 2010.
42. Youdim MB, Edmondson D, and Tipton KF. The therapeutic
potential of monoamine oxidase inhibitors. Nat Rev Neurosci
7: 295–309, 2006.
43. Zhang D, Mott JL, Farrar P, Ryerse JS, Chang SW, Stevens
M, Denniger G, and Zassenhaus HP. Mitochondrial DNA
mutations activate the mitochondrial apoptotic pathway and
cause dilated cardiomyopathy. Cardiovasc Res 57: 147–157,
2003.
Address correspondence to:
Dr. Angelo Parini
INSERM
UMR 1048
Institut des Maladies Me´taboliques et Cardiovasculaires
BP 84225
31432 Toulouse Cedex 4
France
E-mail: angelo.parini@inserm.fr
Date of first submission to ARSCentral, October 28, 2011; date
of final revised submission, May 20, 2012; date of acceptance,
June 2, 2012.
Abbreviations Used
5-HIAA¼ 5-hydroxyindoleacetic acid
5-HT¼ 5-hydroxy-tryptamine
Ade¼ adenovirus
CAT¼ catalase
Clorg¼ clorgyline
CoxIV¼ cytochrome c oxidase IV
DHPG¼dihydroxyphenylglycol
DSWT¼diastolic septal wall thickness
FS¼ fractional shortening
GPX¼ glutathione peroxidase
GSH¼ glutathione reduced
HF¼heart failure
H2O2¼hydrogen peroxide
HPLC¼high performance liquid
chromatography
LDH¼ lactate dehydrogenase
LV¼ left ventricle
LVESD¼ left-ventricular end-systolic diameter
MAO-A¼monoamine oxidase-A
MHC¼myosin heavy chain
Mn-SOD¼ superoxide dismutase
MOI¼multiplicity of infection
NAC¼N-acetyl-cystein
NE¼norepinephrine
Ntg¼nontransgenic
PGC-1a¼peroxisome proliferator-activated
receptor-c coactivator-1a
PWT¼posterior wall thickness
ROS¼ reactive oxygen species
Tg¼ transgenic
TUNEL¼ terminal deoxynucleotidyl transferase
dUTP nick end labeling
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